Vanderhyden Lab

Barbara Vanderhyden profile picture

Contact Information

Barbara Vanderhyden, PhD
613-737-7700 ext. 70330
bvanderhyden@ohri.ca

Ottawa Hospital Research Institute
Centre for Cancer Therapeutics
501 Smyth Road
Box 926
Ottawa, ON K1H 8L6

What We Do

  • Determine how risk factors contribute to ovarian cancer initiation and progression
  • High-throughput genomics to investigate models of ovarian cancer
  • Design, develop, and test novel immune therapies for ovarian cancer
  • Evaluate chromatin remodelling proteins involved in regulating cell state

For information regarding individual projects, please see the Lab Members section

Selected Publications

Hodgkinson K, LA Forrest, N Vuong, K Garson, B Djordjevic, and BC Vanderhyden. (2018). GREB1 is a novel estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. Oncogene Jul 4. doi: 10.1038/s41388-018-0377-y. [Epub ahead of print]

Rodriguez GM, Galpin KJC, McCloskey CW and Vanderhyden BC (2018). The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers (Basel). 10(8). pii: E242. doi: 10.3390/cancers10080242. 

McCloskey CW, Rodriguez GM, Galpin KJC and Vanderhyden BC (2018). Ovarian cancer immunotherapy: Preclinical models and emerging therapeutics. Cancers (Basel). 10(8). pii: E244. doi: 10.3390/cancers10080244.

Vuong NH, O Salah Salah, and BC Vanderhyden (2017). 17β-Estradiol sensitizes ovarian surface epithelium to transformation by suppressing Dab2 expression. Scientific Reports 7: 16,702.

Alwosaibai K, A Abedini, EM Al-Hujaily, Y Tang, K Garson, O Collins and BC Vanderhyden (2017). PAX2 maintains the differentiation of oviductal epithelium and inhibits the transition to a stem cell-like state. Oncotarget 8: 76,881-76,897.

Meet the Vanderhyden Lab